Skip to content
OpenCapital
Get started

JBIO JBIO Change In Fair Value Of Convertible Notes Payable

Change In Fair Value Of Convertible Notes Payable at other companies

ASP Isotopes, Inc. logo
ASP Isotopes, Inc.ASPI
-$568K+40.6%
ASP Isotopes, Inc. logo
ASP Isotopes, Inc.ASPI
-$568K+40.6%
SHA
SharonAI Holdings, Inc. Class A Common StockSHAZ
-$70.23M-979%
Red Cat Holdings, Inc. logo
Red Cat Holdings, Inc.RCAT
-$867K+91.9%
Red Cat Holdings, Inc. logo
Red Cat Holdings, Inc.RCAT
$867K-91.9%
SHA
SharonAI Holdings, Inc. Class A Common StockSHAZ
-$70.23M-979%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K—
Free cash flow-$33.7M—

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B—

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity0×—
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept ck0001798749:ChangeInFairValueOfConvertibleNotesPayable.

The official record: JBIO’s 10-K, filed March 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's change in fair value of convertible notes payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's change in fair value of convertible notes payable?
JBIO (JBIO) reported change in fair value of convertible notes payable of $0 in Q4 2025.
How has JBIO's change in fair value of convertible notes payable changed year-over-year?
JBIO's change in fair value of convertible notes payable decreased by 100.0% year-over-year, from $12.6M to $0.
What does change in fair value of convertible notes payable mean?
This metric represents the non-cash adjustment to net income resulting from changes in the fair market value of convertible debt instruments. For a clinical-stage biotech, it reflects market-driven fluctuations in the valuation of debt that may eventually convert into equity. It is essential for isolating operational cash burn from accounting-driven valuation changes.